Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

39.35USD
21 May 2019
Change (% chg)

$-0.05 (-0.11%)
Prev Close
$39.39
Open
$39.35
Day's High
$39.52
Day's Low
$39.31
Volume
1,321,674
Avg. Vol
2,751,393
52-wk High
$42.36
52-wk Low
$36.41

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $98,615.21
Shares Outstanding(Mil.): 2,459.32
Dividend: 0.50
Yield (%): 6.13

Financials

  GSK Industry Sector
P/E (TTM): 39.40 29.30 32.55
EPS (TTM): 1.03 -- --
ROI: 7.58 14.23 13.82
ROE: 278.84 15.46 15.24

GSK and Novartis liniment marketing misled Australian consumers: court

SYDNEY The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday.

May 17 2019

GSK and Novartis liniment marketing misled Australian consumers -court

SYDNEY, May 17 The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday.

May 17 2019

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

May 08 2019

UPDATE 1-GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

May 9 GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

May 08 2019

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

May 04 2019

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

May 04 2019

GSK's 3-in-1 inhalable drug shows promise in asthma study

British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.

May 02 2019

UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study

May 2 British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.

May 02 2019

GSK's Trelegy Ellipta meets key goal in late-stage asthma study

May 2 British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.

May 02 2019

GSK sees shingles vaccine sales rising, as free cash flow concerns weigh

GlaxoSmithKline forecast on Wednesday that 2019 sales of its shingles vaccine would be more than 1 billion pounds ($1.3 billion) but the British drugmaker's shares slipped on concerns about its pharmaceutical business and free cash flow.

May 01 2019

Earnings vs. Estimates